Top Stories

Pfizer-BioNTech conclude phase 3 study of COVID-19 vaccine, demonstrates 95% efficacy

The Phase 3 study of our COVID-19 vaccine candidate has met all primary efficacy endpoints. The study reached 170 confirmed cases of COVID19, with the vaccine candidate BNT162b2 demonstrating 95% efficacy beginning 28 days after the first dose: Pfizer Inc

Leave a Reply

Your email address will not be published. Required fields are marked *